National Cancer Institute to Grant Exclusive Patent License for Cancer Treatment

Summary

The National Cancer Institute is considering granting an exclusive patent license to Drug Development and Filing Consulting, LLC for the use and development of antisense oligonucleotides targeting RAB13 and NET1 in cancer treatment.